

Supernus – Recall of Trokendi XR[®] (topiramate)

- On December 7, 2016, <u>Supernus announced</u> a consumer-level recall of one packaged lot of <u>Trokendi XR</u> (topiramate) 200 mg extended-release capsules because the lot has improperly placed tamper evident seals that do not meet specification for child-resistance, as required by the Poison Prevention Packaging Act, posing a risk of poisoning if swallowed by children.
 - There is no issue with the internal blister card or drug product. The product is safe for use when used as directed.
- The recalled lot was initially shipped on November 9, 2016 and manufactured by Catalent Pharma Solutions on behalf of Supernus.

Product Description	NDC #	Lot # (expiration date)
Trokendi XR (topiramate) extended-release 200 mg capsules, 30 count blister card	17772-104-15	476916 (6/11/2019)

- Trokendi XR is indicated in patients 6 years of age and older as initial monotherapy for partial onset or
 primary generalized tonic-clonic seizure, and as adjunctive therapy in patients 6 years of age and older
 with partial onset seizures, primary generalized tonic-clonic seizures, and seizures associated with
 Lennox-Gastaut syndrome.
- Healthcare providers, distributers and wholesalers should immediately check inventory, quarantine, and discontinue distribution of the recalled product.
- For any questions regarding this recall, contact Supernus at 1-866-398-0833.

Action Plan

- Clinical Services will conduct mailings to member(s) that may be affected by the Trokendi XR recall, and to providers who prescribed for the drug recently.
- Information regarding Trokendi XR will be posted on the optumrx.com portals.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.